Skip to content

Ultrasonographic Response to Polarized Light Therapy in the Treatment of Atopic Dermatitis

Ultrasonographic Response to Polarized Light Therapy in the Treatment of Atopic Dermatitis

Status
Terminated
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04955951
Enrollment
40
Registered
2021-07-09
Start date
2021-07-01
Completion date
2022-01-15
Last updated
2023-08-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Atopic Dermatitis

Brief summary

Non-atopic dermatitis (NAD) or eczema is a common inflammatory condition; potentially debilitating that can compromise quality of life. It is usually seen in childhood, but can onset within or persist into adulthood.

Detailed description

Polarized ultraviolet-free polychromatic light is used as therapeutic option for the treatment of wound healing and dermatological conditions. 40 male patients who had atopic dermatitis in the chronic stage, they were complaining from itching, inflammation and skin thickness in the arm, wrist, hand and leg will participate in this study.

Interventions

A Bioptron light therapy phototherapeutic device (Bioptron AG, Wollerau, Switzerland) with 5 cm treatment diameter (BIOPTRON MedAll®, 480-3400 nm, polarization level of 95%, power density 40 mW/cm2, energy density 2,4 J/cm2 per minute

DRUGTopical corticosteroid ointment

corticosteroid 1 %.

Sponsors

Ahram Canadian University
Lead SponsorOTHER

Study design

Observational model
CASE_ONLY
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
MALE
Age
20 Years to 30 Years
Healthy volunteers
No

Inclusion criteria

* The patients' ages will ranged from 20 to 30 years. * The subjects will be males. * The duration of disease less than 1 year.

Exclusion criteria

* patients who had skin malignancy in the area to be treated. * The patients who had history of diabetes, circulatory or sensory disorders. * Patients with acute infection in the area treated.

Design outcomes

Primary

MeasureTime frameDescription
Ultrasonography1-2 monthsUltrasound imaging system used to measure the thickness of the skin at the site of scale for both groups

Secondary

MeasureTime frameDescription
SCORAD Score1-2 monthsThe SCORAD (Index) is the best validated scoring system in atopic dermatitis, To measure the extent of AD, the rule of nines is applied on a front/back drawing of the patient's inflammatory lesions. The extent can be graded from 0 to 100. The intensity part of the SCORAD consists of 6 items: erythema, oedema/papulation, excoriations, lichenification, oozing/crusts and dryness. Each item can be graded on a scale from 0 to 3. The subjective items include daily pruritus and sleeplessness. The SCORAD Index formula is: A/5 + 7B/2 + C. In this formula A is defined as the extent (0-100), B is defined as the intensity (0-18) and C is defined as the subjective symptoms (0-20). The maximal score of the SCORAD Index is 103. The objective SCORAD consist of the extent and the intensity items; the formula is A/5 + 7B/2. The maximal objective SCORAD score is 83 (with 10 additional points for severe disfiguring eczema of the face and hands).

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026